The conference will address the challenges and future directions in Immuno-Oncology research, and on day 2 of the conference, June 24th, Lytix will present how to address Tumor Heterogeneity with non-viral Oncolytic agents - an unsolved issue in Cancer Immunotherapy.

Oncolytic molecules have shown ability to kill drug resistant and drug sensitive cancer cells and evoke the innate immune system, and clinical results demonstrate promising potential for combining Lytix’ oncolytic molecules with immune checkpoint inhibitors or adoptive T-cell therapies.

See conference website for more info.